Edwards Lifesciences Corp

EW: XNYS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
v#kLOCK|!#%vLOCK|mm^>?d%

Edwards Lifesciences Earnings: Indication Expansion to Asymptomatic Should Support TAVR Growth

Edwards posted second-quarter earnings that featured 9% top-line and 16% adjusted bottom-line growth, fueled by an acceleration in transcatheter aortic valve replacement, or TAVR, along with strong adoption of transcatheter mitral and tricuspid devices.

Sponsor Center